🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Concentra sets IPO price range, aims for NYSE listing

EditorAhmed Abdulazez Abdulkadir
Published 15/07/2024, 14:12
SEM
-

MECHANICSBURG, Pa. - Select Medical (NYSE:SEM) Holdings Corporation (NYSE: SEM) announced that its wholly owned subsidiary, Concentra Group Holdings Parent, Inc., has initiated a roadshow to launch its initial public offering (IPO) of 22.5 million shares of common stock. The IPO price is anticipated to range from $23.00 to $26.00 per share, with Concentra also offering underwriters a 30-day option to buy an additional 3.375 million shares for potential over-allotments.

Concentra, which is set to trade on the New York Stock Exchange under the ticker "CON," is navigating market conditions to finalize the IPO size and terms. The offering's completion is dependent on market receptivity and other factors, with no guarantees regarding the finalization or timing of the IPO.

Upon the IPO's closure, Select Medical will retain a majority stake in Concentra, holding 104,093,503 shares, or 82.23% of the total outstanding shares, which could decrease to 80.09% if underwriters fully exercise their over-allotment option.

Leading financial institutions J.P. Morgan, Goldman Sachs (NYSE:GS) & Co. LLC, and BofA Securities are the main book-runners for the offering. Additional joint book-runners include Deutsche Bank (ETR:DBKGn) Securities, Wells Fargo (NYSE:WFC) Securities, Mizuho, RBC Capital Markets, and Truist Securities, with several other firms serving as co-managers.

Select Medical, a prominent player in the healthcare sector, operates an extensive network of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers across the United States.

This news article is based on a press release statement from Select Medical Holdings Corporation.

In other recent news, Select Medical Holdings Corporation reported a strong first quarter with a 22% increase in adjusted EBITDA and a 7% rise in revenue year-over-year. The company's Critical Illness Recovery hospitals experienced significant growth, contributing to its overall robust performance. Furthermore, Select Medical's occupational health services business, Concentra, has initiated a $750 million senior notes offering as part of a broader plan to separate Concentra from Select Medical.

The company's performance has been positively assessed by analysts at Benchmark and RBC Capital, leading to raised price targets. Benchmark increased its target to $42, while RBC Capital raised its target to $40, both maintaining their respective Buy and Outperform ratings.

In addition to these developments, Select Medical has announced plans for the Concentra spin-off, expected to be completed by the end of 2024. The company also plans to expand its operations by adding 537 beds by 2026.

InvestingPro Insights

As Select Medical Holdings Corporation (NYSE: SEM) gears up for the IPO of its subsidiary, Concentra Group Holdings Parent, Inc., investors are closely monitoring the company's financial health and market position. InvestingPro data provides a snapshot of Select Medical's current standing, with a market capitalization of $4.87 billion and a P/E ratio of 17.78, which adjusts slightly higher to 18.13 on a last twelve months basis as of Q1 2024.

The company's revenue growth has been steady, with a 6.08% increase over the last twelve months as of Q1 2024, and an even more robust quarterly revenue growth of 7.44% in Q1 2024. This financial stability is further underscored by a gross profit of $1.37 billion and a gross profit margin of 20.13% in the same period.

InvestingPro Tips highlight that analysts have recently revised their earnings expectations downwards for the upcoming period, which could be a point of consideration for potential investors. Additionally, the Relative Strength Index (RSI) suggests that the stock is currently in overbought territory, indicating that it may be due for a pullback or consolidation in the near term.

Despite these cautionary signals, Select Medical has demonstrated strong performance with a significant price uptick over the last six months, boasting a 43.14% total return in that period. Moreover, the company's stock is trading near its 52-week high, with a price that is 99.15% of this peak value.

For those interested in a deeper dive into Select Medical's forecast and financial analysis, there are additional InvestingPro Tips available at https://www.investing.com/pro/SEM. By using the coupon code PRONEWS24, readers can get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking even more expert insights to inform their investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.